ArticleCellular oncology (Dordrecht, Netherlands)2024

Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma.

Xiangke Xin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.